Vyome Therapeutics Secures Nasdaq Approval for Merger with ReShape Lifesciences, Targeting $100B Inflammatory Disease Market
核心洞察
Vyome Therapeutics (搜索) received Nasdaq approval for its merger with ReShape Lifesciences, set to begin trading as "HIND" on August 15, 2025.
The clinical-stage company focuses on immuno-inflammatory and rare diseases (搜索), targeting a market exceeding $100 billion in inflammatory conditions.
Vyome's existing clinical-stage assets address major unmet medical needs in the immuno-inflammatory space, developed over years of research.
Vyome Therapeutics (搜索), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases (搜索), has received approval from The Nasdaq Stock Market for its listing following completion of its merger with ReShape Lifesciences (Nasdaq: RSLS). The combined entity will begin trading on August 15, 2025, under the name Vyome Holdings (搜索), Inc. with the ticker symbol "HIND."
Strategic Focus on Inflammatory Disease Market
The merger positions Vyome to address what founder Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School, describes as "one of the most impactful chronic conditions afflicting humanity today." According to Sengupta, inflammatory diseases (搜索) represent a market exceeding $100 billion, with conditions "all connected to our immune system (搜索) not functioning as it should."
Vyome's clinical-stage assets, developed over years of research, specifically target major unmet indications in the immuno-inflammatory space. The company's approach addresses the substantial medical need in treating various inflammatory conditions that affect patients globally.
Corporate Structure and Trading Details
In connection with the merger completion and Nasdaq requirements, ReShape's Board of Directors has declared a 1-for-4 reverse stock split of the company's common stock, effective August 15, 2025. Under this arrangement, each four shares of issued and outstanding common stock and equivalents will convert into one share of common stock. The new CUSIP number for the company's common stock following the reverse stock split and merger will be 92943X104.
The reverse split will not impact the post-merger ownership allocations between ReShape and Vyome shareholders in the transaction.
Leadership Vision and Market Positioning
Krishna Gupta, Chairman of Vyome, emphasized the company's commitment to shareholder value and its strategic positioning in the global healthcare market. "If you believe in the global healthcare market, in the opportunities to do business between the US and India, and in the value of a group of smart people driving real innovation across science and AI, you believe in Vyome," Gupta stated.
The company's focus extends beyond the US market to include global opportunities, particularly leveraging connections between American and Indian healthcare sectors. This international approach reflects Vyome's strategy to address immuno-inflammatory and rare diseases (搜索) across multiple markets with significant growth potential.